Todd Cooperman, PharmD, RPh, PAHM

Pharmacists can collaborate with oncologists to maximize patient outcomes through appropriate dispensing, side-effect monitoring, and adherence.

Researchers assess new study models and investigate triple drug therapies to fight hepatitis C infection.

The blood modifier category of drugs works stimulating bone marrow to produce more cells and they affect certain diseases such as cancer and chronic kidney failure.

The next evolutionary step for specialty medications could lead to a new generation of cost-effective, noninvasive treatments for heart disease.

Newer pharmaceutical agents for the treatment of type 2 diabetes suggest a movement toward diabetes becoming a specialty disease state.

Pharmacists can collaborate with oncologists to maximize patient outcomes through appropriate dispensing, side-effect monitoring, and adherence.